MENU
+Compare
STOK
Stock ticker: NASDAQ
AS OF
Dec 20, 04:59 PM (EDT)
Price
$11.66
Change
+$0.36 (+3.19%)
Capitalization
618.65M

STOK Stoke Therapeutics Forecast, Technical & Fundamental Analysis

a company, which engages in the research and development of treatments for genetic diseases.

Industry Biotechnology
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
a Summary for STOK with price predictions
Dec 20, 2024

STOK in +5.13% Uptrend, rising for three consecutive days on December 20, 2024

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where STOK advanced for three days, in of 288 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where STOK's RSI Indicator exited the oversold zone, of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 18, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on STOK as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for STOK turned negative on December 17, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .

STOK moved below its 50-day moving average on December 12, 2024 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for STOK crossed bearishly below the 50-day moving average on December 19, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

The 50-day moving average for STOK moved below the 200-day moving average on November 29, 2024. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where STOK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

STOK broke above its upper Bollinger Band on December 06, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for STOK entered a downward trend on December 20, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.665) is normal, around the industry mean (14.556). P/E Ratio (0.000) is within average values for comparable stocks, (87.563). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.739). STOK has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (35.587) is also within normal values, averaging (256.215).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. STOK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STOK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

STOK is expected to report earnings to rise 16.55% to -54 cents per share on March 05

Stoke Therapeutics STOK Stock Earnings Reports
Q4'24
Est.
$-0.55
Q3'24
Beat
by $0.07
Q2'24
Beat
by $0.09
Q1'24
Beat
by $0.05
Q4'23
Beat
by $0.04
The last earnings report on November 05 showed earnings per share of -46 cents, beating the estimate of -54 cents. With 1.18M shares outstanding, the current market capitalization sits at 618.65M.
A.I. Advisor
published General Information

General Information

a company, which engages in the research and development of treatments for genetic diseases.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
45 Wiggins Avenue
Phone
+1 781 430-8200
Employees
110
Web
https://www.stoketherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FNPIX42.400.86
+2.07%
ProFunds Financials UltraSector Inv
DEIGX11.290.11
+0.98%
MassMutual Disciplined Gr Svc
BHEIX27.880.25
+0.90%
BlackRock High Equity Income K
HSMCX18.240.15
+0.83%
Hartford Small Company C
FECMX38.540.11
+0.29%
Fidelity Advisor Emerging Markets I

STOK and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, STOK has been loosely correlated with NUVB. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if STOK jumps, then NUVB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STOK
1D Price
Change %
STOK100%
+3.36%
NUVB - STOK
51%
Loosely correlated
-0.37%
STRO - STOK
48%
Loosely correlated
+3.30%
INZY - STOK
46%
Loosely correlated
+6.41%
QTTB - STOK
44%
Loosely correlated
+7.49%
DNLI - STOK
43%
Loosely correlated
-0.19%
More